Since December 2019, a viral pneumonia, named coronavirus disease 2019 (COVID-19),
from Wuhan, China, has swept the world. Although the case fatality rate is not high, the …

Since December 2019, a novel coronavirus pneumonia (COVID-19) has broken out in
Wuhan, China and spread rapidly. Recent studies have found that⁓ 15.7% of patients …

Cytokine release syndrome (CRS) may be the key factor in the pathology of severe
coronavirus disease 2019 (COVID-19). As a major driver in triggering CRS in patients with …

Excessive interleukin-6 signaling is a key factor contributing to the cytokine release
syndrome implicated in clinical manifestations of COVID-19. Preliminary results suggest that …

Objectives Cytokine release syndrome with elevated interleukin-6 (IL-6) levels is associated
with multiorgan damage and death in severe coronavirus disease 2019 (COVID-19). Our …

COVID-19, caused by the novel severe acute respiratory coronavirus 2 (SARS-CoV-2),
emerged in Wuhan, China, in 2019 and has resulted in the current pandemic. The disease …

Novel coronavirus disease 2019 (COVID-19) emerged in late December 2019 in Wuhan,
China. Since then, COVID-19 has become a pandemic affecting more than 4.1 million …

Presently, we need more therapeutic molecules for this COVID-19 outbreak. The severity
and mortality of the disease is associated with a high level of release of cytokine in the …

Since cytokine release syndrome with elevation of interleukin‐6 (IL‐6) is considered to be
associated with severe cases of coronavirus disease 2019 (COVID‐19); IL‐6 inhibitors, such …

Background Tocilizumab, an IL-6 receptor antagonist, can be used to treat cytokine release
syndrome (CRS), with observed improvements in a coronavirus disease 2019 (COVID-19) …